Faegre Drinker Biddle & Reath LLP, a Delaware limited liability partnership | This website contains attorney advertising.
September 2018

Boston Scientific Corporation Acquires Augmenix Inc. in up to $600M Deal

Asia | Asia - Japan | North America - United States | Europe | Europe - United Kingdom | North America | United States - Massachusetts

Boston Scientific Corporation acquired Augmenix Inc., a privately held developer of a novel therapy to reduce side effects from radiation aimed at the prostate. Our firm represented Boston Scientific in the transaction. The transaction consists of an upfront cash payment of $500 million, and up to $100 million for reaching sales-based milestones.

Read Boston Scientific's press release for more information on the deal.

Related Legal Services

The Faegre Drinker Biddle & Reath LLP website uses cookies to make your browsing experience as useful as possible. In order to have the full site experience, keep cookies enabled on your web browser. By browsing our site with cookies enabled, you are agreeing to their use. Review Faegre Drinker Biddle & Reath LLP's cookies information for more details.